NephroGenex Priced, Nasdaq: NRX
Clinical-stage biotech developing treatments for diabetic nephropathy.
Industry: Health Care
First Day Return: -3.8%
NRX
Clinical-stage biotech developing treatments for diabetic nephropathy.
| IPO Data | |
|---|---|
| IPO Date | 02/10/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $37 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Research Triangle Park, NC, United States |
| Founded | 2004 |
| Employees at IPO | 10 |
| Website www.nephrogenex.com | |
IPO News for NephroGenex
NephroGenex (NRX) Performance
